RGEN (Repligen) Quality Rank


RGEN Repligen Corp RGEN
84 GF Score
Price $138.61
GF Value $176.53
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Repligen Quality Rank Related Terms

RGEN
84GF Score
Repligen Corp RGEN
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $138.61 is trading 21.5% below its estimated GF Value™ of $176.53. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Quality Rank:
  • GF Value™: $176.53 vs. price of $138.61 (21.5% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
84GF Score

Get the complete analysis for RGEN

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$138.61
Price
$176.53
GF Value